Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders.

ABSTRACT:

Purpose

Tumour genomic profiling is of increasing importance in early phase trials to match patients to targeted therapeutics. Mutations vary by demographic group; however, regional differences are not characterised. This was investigated by comparing mutation prevalence for common cancers presenting to Newcastle Experimental Cancer Medicine Centre (ECMC) to The Cancer Genome Atlas (TCGA) and utility of trial matching modalities.

Methods

Detailed clinicogenomic data were obtained for patients presenting September 2017-December 2020. Prevalence of mutations in lung, colorectal, breast and prostate cancer was compared to TCGA GDC Data Portal. Experimental Cancer (EC) Trial Finder utility in matching trials was compared to a Molecular Tumour Board (MTB) and commercial sequencin

SUBMITTER: Rae S 

PROVIDER: S-EPMC10645649 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature